Biotech Values

[iwfal]

MNTA’s motivation for lowballing the prep time to get ready for trial is exactly analogous—in reverse—to Amphastar’s motivation for exaggerating it.

So, Momenta intends to convince the judge of the impact to their company by lowballing how much time they have reduced revenues. And Amphastar intends to convince the judge of the impact to their company by highballing how much time they have reduced revenues. One side or the other is completely incompetent.